Characteristics of monoclonal antibodies tested in the amelioration of murine ITP
| Tissue distribution of antigen in SCID mice . | Efficacy in ITP* . | Monoclonal antibodies . | Isotype . | Clone . | ||
|---|---|---|---|---|---|---|
| 50 μg . | 5 μg . | 0.5 μg . | ||||
| None | − | − | − | IgG1isotype control | IgG1, λ | A110-1 |
| None | − | − | − | IgG2a isotype control | IgG2a, κ | A110-2 |
| None | − | − | − | IgG2b isotype control | IgG2b, κ | A95-1 |
| None | − | − | − | IgG2c isotype control | IgG2c, κ | A23-1 |
| None | − | − | − | Anti–IL-2 | IgG2a | JES6-1A12 |
| None | − | − | − | Anti-IgG2a/2b | IgG1, κ | R2-40 |
| None | − | − | − | Anti-IgA | IgG1, κ | C10-1 |
| None | − | − | − | Anti-IgG1 | IgG2, κ | A85-1 |
| None | − | − | − | Anti-IgD | IgG2a, κ | 11-26c.2a |
| RBC | + | ± | − | Anti–TER-119 | IgG2b | TER-119 |
| RBC, PMN, Mφ | + | + | − | Anti-CD24 | IgG2b, κ | M1/69 |
| RBC, PMN, Mφ | − | − | − | Anti-CD24 | IgG2c, κ | 30-F1 |
| RBC, PMN, Mφ | − | − | − | Anti-CD24 | IgM, κ | J11d |
| RBC, PMN, Mφ | − | − | − | Anti-CD24 | IgM | IOTHSA |
| All cells† | + | + | − | Anti-CD44 | IgG1, κ | KM114 |
| All cells† | − | − | − | Anti-CD44 | IgG2b, κ | IM7 |
| All cells | − | − | − | Anti-CD47 | IgG2a, κ | Miap301 |
| NK, Mφ, PMN | + | − | − | Anti-CD16/32 | IgG2b, κ | 2.4G2 |
| RBC, PMN, Mφ | − | − | − | Anti-CD126 | IgG2b, κ | D7715A7 |
| PMN, Mφ, NK | − | − | − | Anti-CD11b | IgG2b, κ | M1/70 |
| Mφ, PMN | − | − | − | Anti-CD21/35 | IgG2b, κ | 7G6 |
| Tissue distribution of antigen in SCID mice . | Efficacy in ITP* . | Monoclonal antibodies . | Isotype . | Clone . | ||
|---|---|---|---|---|---|---|
| 50 μg . | 5 μg . | 0.5 μg . | ||||
| None | − | − | − | IgG1isotype control | IgG1, λ | A110-1 |
| None | − | − | − | IgG2a isotype control | IgG2a, κ | A110-2 |
| None | − | − | − | IgG2b isotype control | IgG2b, κ | A95-1 |
| None | − | − | − | IgG2c isotype control | IgG2c, κ | A23-1 |
| None | − | − | − | Anti–IL-2 | IgG2a | JES6-1A12 |
| None | − | − | − | Anti-IgG2a/2b | IgG1, κ | R2-40 |
| None | − | − | − | Anti-IgA | IgG1, κ | C10-1 |
| None | − | − | − | Anti-IgG1 | IgG2, κ | A85-1 |
| None | − | − | − | Anti-IgD | IgG2a, κ | 11-26c.2a |
| RBC | + | ± | − | Anti–TER-119 | IgG2b | TER-119 |
| RBC, PMN, Mφ | + | + | − | Anti-CD24 | IgG2b, κ | M1/69 |
| RBC, PMN, Mφ | − | − | − | Anti-CD24 | IgG2c, κ | 30-F1 |
| RBC, PMN, Mφ | − | − | − | Anti-CD24 | IgM, κ | J11d |
| RBC, PMN, Mφ | − | − | − | Anti-CD24 | IgM | IOTHSA |
| All cells† | + | + | − | Anti-CD44 | IgG1, κ | KM114 |
| All cells† | − | − | − | Anti-CD44 | IgG2b, κ | IM7 |
| All cells | − | − | − | Anti-CD47 | IgG2a, κ | Miap301 |
| NK, Mφ, PMN | + | − | − | Anti-CD16/32 | IgG2b, κ | 2.4G2 |
| RBC, PMN, Mφ | − | − | − | Anti-CD126 | IgG2b, κ | D7715A7 |
| PMN, Mφ, NK | − | − | − | Anti-CD11b | IgG2b, κ | M1/70 |
| Mφ, PMN | − | − | − | Anti-CD21/35 | IgG2b, κ | 7G6 |
+ denotes that the antibody effected a significant amelioration of thrombocytopenia at that dose; ±, the antibody effected a slight amelioration of thrombocytopenia at that dose; −, the antibody did not ameliorate thrombocytopenia at that dose; RBC, red blood cell; PMN, polymorphonuclear leukocyte; Mφ, monocyte/macrophage; and NK, natural killer cell.
ITP was induced in SCID mice by intraperitoneal injection of anti-αIIb antibody.
Except RBC and endothelial cells.